GleamWall
中文EN

ARVN ARVINAS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1655759 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.8%
TTM net income YoY83.8%
TTM EPS YoY90.1%
Revenue 3-yr CAGR18.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12.1%
Net margin-3.5%
FCF margin-58.0%
EBITDA margin-11.2%

Returns

ROE-1.8%
ROA-1.3%
ROIC (approx.)-5.9%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets15.4%
Debt / equity0.00x
Current ratio8.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income16.66x
Accruals ratio20.5%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$500,000$249.70M$15.60M$9.50M$41.90M$22.40M$188.80M$59.20M
R&D expense$46.90M$52.60M$60.30M$61.10M$64.70M$68.60M$90.80M$83.30M
SG&A expense$12.60M$24.00M$19.10M$23.00M$21.00M$25.30M$26.60M$34.10M
Operating income-$59.10M$164.10M-$63.80M-$74.60M-$43.80M-$71.50M$71.40M-$58.20M
Interest expense$0$0——$0$0$0$0
Pretax income-$53.70M$169.60M-$57.50M-$67.20M-$34.80M-$61.50M$83.10M-$45.50M
Income tax$200,000$200,000$100,000$200,000$300,000-$300,000$200,000-$400,000
Net income-$53.90M$169.40M-$57.60M-$67.40M-$35.10M-$61.20M$82.90M-$45.10M
EBITDA-$58.50M$164.80M-$63.10M-$73.90M-$43.00M-$70.70M$72.10M-$57.10M
EPS (basic)-0.822.61-0.90—-0.48-0.841.14—
EPS (diluted)-0.822.58-0.90—-0.48-0.841.14—
Weighted avg. shares (diluted)65.40M65.70M64.00M—73.20M73.00M72.70M—
Balance sheet
Cash & equivalents$88.00M$94.30M$87.30M$142.90M$101.50M$114.90M$81.00M$100.50M
Short-term investments$470.40M$473.60M$527.60M$542.50M$686.10M$746.30M$873.30M$938.90M
Receivables$1.80M$50.30M$1.80M$1.00M$20.30M$500,000$400,000$5.70M
Current assets$587.60M$652.20M$630.70M$700.70M$826.30M$889.50M$979.70M$1.07B
PP&E, net$4.60M$5.00M$5.50M$5.20M$5.40M$6.10M$6.70M$7.00M
Total assets$607.50M$675.10M$647.50M$717.90M$844.30M$909.30M$1.00B$1.09B
Current liabilities$70.00M$82.50M$115.90M$142.50M$144.90M$157.80M$214.00M$229.80M
Short-term debt$200,000$200,000$200,000$200,000$200,000$200,000$200,000$200,000
Long-term debt$200,000$300,000$300,000$400,000$400,000$500,000$500,000$600,000
Total debt$400,000$500,000$500,000$600,000$600,000$700,000$700,000$800,000
Total liabilities$93.70M$112.90M$260.70M$284.00M$279.90M$300.00M$341.00M$529.70M
Shareholders' equity$513.80M$562.20M$386.80M$433.90M$564.40M$609.30M$660.10M$561.70M
Net debt-$87.60M-$93.80M-$86.80M-$142.30M-$100.90M-$114.20M-$80.30M-$99.70M
Shares outstanding65.50M65.30M64.50M63.50M70.80M73.20M73.00M68.80M
Cash flow statement
Operating cash flow-$10.40M-$48.30M-$69.20M-$30.40M-$59.10M-$95.40M-$88.90M-$84.10M
Capital expenditure-$200,000$200,000$1.30M$200,000$100,000$1.20M$400,000$300,000
Free cash flow-$10.20M-$48.50M-$70.50M-$30.60M-$59.20M-$96.60M-$89.30M-$84.40M
Investing cash flow$4.20M$54.90M$13.70M$145.80M$63.50M$128.80M$69.50M$98.90M
Financing cash flow$400,000$400,000-$100,000-$74.00M-$17.80M$500,000-$100,000$500,000
Depreciation & amortization$600,000$700,000$700,000$700,000$800,000$800,000$700,000$1.10M
Stock-based compensation$5.90M$5.90M$12.10M$8.50M$10.10M$10.40M$15.00M$23.30M
Share buybacks———$74.10M———$0

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.